{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:29:23Z","timestamp":1787711363281,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ophtha.2025.06.018","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:22:41Z","timestamp":1750792961000},"page":"1241-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7176-6631","authenticated-orcid":false,"given":"Keean","family":"Nanji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Grad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Hatamnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"McKechnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Ming","family":"Gemmy Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Dolz","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Guymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-4146","authenticated-orcid":false,"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2025.06.018_bib1","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","author":"Bourne","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ophtha.2025.06.018_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-66014-7_1","article-title":"Age-related macular degeneration: epidemiology and clinical aspects","volume":"1256","author":"Keenan","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib3","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2025.06.018_bib4","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ophtha.2015.09.039","article-title":"First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration","volume":"123","author":"Talks","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.06.018_bib7","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2025.06.018_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jamaophthalmol.2020.5044","article-title":"Insights from survival analyses during 12 years of anti\u2013vascular endothelial growth factor therapy for neovascular age-related macular degeneration","volume":"139","author":"Fu","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib9","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.06.018_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41433-022-02221-0","article-title":"Treat and extend in neovascular age-related macular degeneration: how we got here and where do we go next?","volume":"37","author":"Chaudhary","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2025.06.018_bib11","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ophtha.2025.06.018_bib12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","article-title":"Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2025.06.018_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-021-02055-6","article-title":"Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study","volume":"21","author":"Corazza","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/IAE.0000000000000827","article-title":"Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration","volume":"36","author":"Arevalo","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2025.06.018_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.ophtha.2025.06.018_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/aos.14537","article-title":"Changes in aqueous and vitreous inflammatory cytokine levels in neovascular age-related macular degeneration: a systematic review and meta-analysis","volume":"99","author":"Minaker","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.oret.2020.08.003","article-title":"Home monitoring of age-related macular degeneration: utility of the ForeseeHome device for detection of neovascularization","volume":"5","author":"Yu","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2025.06.018_bib18","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/s41433-022-02360-4","article-title":"Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review","volume":"37","author":"Hanson","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2025.06.018_bib19","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41433-022-02154-8","article-title":"Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)\u2014a phase III, prospective, multicentre, randomized study: design and methods","volume":"37","author":"Coulibaly","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2025.06.018_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular morphology and visual acuity in year five of the Comparison of Age-related Macular Degeneration Treatments Trials","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.06.018_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ophtha.2015.09.013","article-title":"Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.06.018_bib22","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/IAE.0000000000001748","article-title":"Prognostic value of subretinal hyperreflective material in neovascular age-related macular degeneration treated with bevacizumab","volume":"38","author":"Pokroy","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2025.06.018_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","article-title":"A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration","volume":"50","author":"Schmidt-Erfurth","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2025.06.018_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","article-title":"GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks","volume":"121","author":"Foroutan","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib25","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2025.06.018_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"13","author":"Collins","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.ophtha.2025.06.018_bib27","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1475-1313.2010.00766.x","article-title":"Transforming scales of measurement of visual acuity at the group level","volume":"30","author":"Khoshnood","year":"2010","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.ophtha.2025.06.018_bib28","article-title":"How to obtain the confidence interval from a P value","volume":"343","author":"Altman","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2025.06.018_bib30","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.06.018_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2022.08.012","article-title":"DIAbetic Macular Oedema aNd Diode Subthreshold micropulse laser (DIAMONDS): a randomized double-masked non-inferiority clinical trial","volume":"130","author":"Lois","year":"2023","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2025.06.018_bib32","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/j.jcjo.2024.05.027","article-title":"Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration","volume":"60","author":"Nanji","year":"2025","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib33","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2014publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ophtha.2025.06.018_bib36","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to Assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"issue":"6","key":"10.1016\/j.ophtha.2025.06.018_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056400","article-title":"Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study","volume":"12","author":"Phillips","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ophtha.2025.06.018_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2017.12.019","article-title":"Evolution of intravitreal therapy for retinal diseases - from CMV to CNV: the LXXIV Edward Jackson Memorial Lecture","volume":"191","author":"Martin","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib40","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.06.018_bib41","first-page":"1","article-title":"Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review","volume":"2022","author":"Hanson","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2025.06.018_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9994098","article-title":"OCT biomarkers in neovascular age-related macular degeneration: a narrative review","volume":"2021","author":"Metrangolo","year":"2021","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.06.018_bib43","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.3390\/jcm12093049","article-title":"Prognostic optical coherence tomography biomarkers in neovascular age-related macular degeneration","volume":"12","author":"Nawash","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ophtha.2025.06.018_bib44","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","article-title":"Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD","volume":"35","author":"Chakravarthy","year":"2021","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025003896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025003896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:38:48Z","timestamp":1774859928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025003896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0161642025003896"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.06.018","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}